20th May 2008 13:00
Annual Information Update
Basingstoke, UK - 20 May 2008 - Shire plc (the "Company") , the global specialty biopharmaceutical company, announces the Annual Information Update in accordance with the requirements of Prospectus Rule 5.2.1R. This is in relation to information that has been published or made available to the public between 20 June 2007 and 19 May 2008.
This Annual Information Update is also being made available on the Investors section of the Company's website, www.shire.com.
The information referred to in this Annual Information Update was correct at the time the information was published, but some information may now be out of date. The information appears by way of record and the Company is under no obligation to update it.
1. Announcements made via a RIS
The documents listed below were published via a Regulatory Information Service on or around the dates indicated.
Date Announcement 09-May-08 Result of EGM 01-May-08 Total Voting Rights 01-May-08 Shire welcomes the Court of Appeal's decision 30-Apr-08 Holding(s) in Company 29-Apr-08 Publication of Supplementary Prospectus 25-Apr-08 Good start to the year reaffirms full year 2008 guidance 24-Apr-08 Dr Michael Rosenblatt appointed Non-Executive Director 24-Apr-08 Shire enhances its orphan drug pipeline 23-Apr-08 FDA Approves VYVANSE to Treat ADHD in Adults 16-Apr-08 New Shire Holding Company Proposal 16-Apr-08 Notice of Results 15-Apr-08 SHIRE TO INTRODUCE A NEW UK LISTED HOLDING COMPANY 04-Apr-08 Annual Report and Accounts 02-Apr-08 Director/PDMR Shareholding 01-Apr-08 Total Voting Rights 31-Mar-08 Director/PDMR Shareholding 26-Mar-08 Shire and TAP Agree to Co-promote LIALDA 26-Mar-08 Director/PDMR Shareholding 25-Mar-08 IFRS results for the year ending December 31, 2007 03-Mar-08 Renovo announces results of latest JUVISTA P2 studies 03-Mar-08 Total Voting Rights 26-Feb-08 Director/PDMR Shareholding 25-Feb-08 Director/PDMR Shareholding 21-Feb-08 Notification of major interests in shares 21-Feb-08 Full year 2007 results 20-Feb-08 Correction re website 13-Feb-08 Shire's ELAPRASE Approved in Mexico 12-Feb-08 Full Year Results Date Notification - 21 February 2008 12-Feb-08 Notification of major interests in shares 01-Feb-08 Total Voting Rights 03-Jan-08 Total Voting Rights - Correction 02-Jan-08 Total Voting Rights 21-Dec-07 Director/PDMR Shareholding 19-Dec-07 Application for Block Listing 17-Dec-07 Holdings in Company 14-Dec-07 Shire In-licensing Agreement Alba Therapeutics 13-Dec-07 Board Changes 07-Dec-07 Holding(s) in Company 05-Dec-07 Holding(s) in Company 03-Dec-07 Total Voting Rights 29-Nov-07 Acquisition of Shares 26-Nov-07 Blocklisting - Interim Review 08-Nov-07 Shire expands its HGT pipeline through in-licensing 02-Nov-07 Director/PDMR Shareholding 02-Nov-07 Director/PDMR Shareholding 01-Nov-07 Total Voting Rights 01-Nov-07 Further upgrade to 2007 financial guidance - Q3 Results 31-Oct-07 David Mott appointed Non Executive Director at Shire 17-Oct-07 Correction: Notice of Results 17-Oct-07 Notice of Results 08-Oct-07 Shire divests non-core product portfolio to Almirall 05-Oct-07 ELAPRASE Approved in Japan 01-Oct-07 Total Voting Rights 24-Sep-07 Shire Appoints Sylvie Gregoire President of HGT 21-Sep-07 Holding(s) in Company 17-Sep-07 Availability of 2007 Interim at UKLA Document Viewing 13-Sep-07 IFRS Information - First half of 2007 12-Sep-07 Director/PDMR Shareholding 12-Sep-07 Director/PDMR Shareholding 03-Sep-07 Total Voting Rights 15-Aug-07 Expiry of Hart-Scott-Rodino waiting period for JUVISTA 07-Aug-07 Director/PDMR Shareholding 03-Aug-07 Director/PDMR Shareholding 02-Aug-07 Notification of the Exercise of an Option 02-Aug-07 Notification of major interests in shares 02-Aug-07 Total Voting Rights 27-Jul-07 Application for Share Listing 26-Jul-07 2007 guidance upgraded as revenue growth accelerates 25-Jul-07 Shire Board Changes 19-Jul-07 Q2 2007 results Timing of meeting changed 18-Jul-07 Q2 2007 results date notification - 26 July 2007 02-Jul-07 Total Voting Rights 02-Jul-07 Filing of VYVANSE for the Treatment of ADHD in Adults 25-Jun-07 Notification of major interests in shares 21-Jun-07 Shire Receives FDA Approvable Letter for INTUNIV(TM) 20-Jun-07 Result of AGM 20-Jun-07 Holding(s) in Company 20-Jun-07 Shire in-licenses JUVISTA(R) (human TGFB3) from Renovo 20-Jun-07 Annual Information Update
2. Documents filed at Companies House
All documents listed below were filed with the Registrar of Companies in England and Wales on or around the dates indicated, and can be obtained from Companies House via their website www.companieshouse.gov.uk.
Date Document 22/06/2007 Forms 88(2)R - Return of an Allotment of Shares 26/06/2007 Forms 88(2)R - Return of an Allotment of Shares 02/07/2007 Forms 88(2)R - Return of an Allotment of Shares 06/07/2007 Resolution - Disapplication of pre-emption rights and authority to allot shares 10/07/2007 Forms 88(2)R - Return of an Allotment of Shares 23/07/2007 Forms 88(2)R - Return of an Allotment of Shares 27/07/2007 Forms 88(2)R - Return of an Allotment of Shares 09/08/2007 Forms 88(2)R - Return of an Allotment of Shares 13/08/2007 Form 88(2)R - Return of an Allotment of Shares 14/08/2007 Forms 88(2)R - Return of an Allotment of Shares 23/08/2007 Forms 88(2)R - Return of an Allotment of Shares 31/08/2007 Forms 88(2)R - Return of an Allotment of Shares 05/09/2007 Forms 88(2)R - Return of an Allotment of Shares 28/09/2007 Forms 88(2)R - Return of an Allotment of Shares 05/10/2007 Forms 88(2)R - Return of an Allotment of Shares 19/10/2007 Forms 88(2)R - Return of an Allotment of Shares 02/11/2007 Forms 88(2)R - Return of an Allotment of Shares 13/11/2007 Forms 88(2)R - Return of an Allotment of Shares 16/11/2007 Forms 88(2)R - Return of an Allotment of Shares 06/12/2007 Forms 88(2)R - Return of an Allotment of Shares 13/12/2007 Forms 88(2)R - Return of an Allotment of Shares 19/12/2007 Form 88(2)R - Return of an Allotment of Shares 21/12/2007 Forms 88(2)R - Return of an Allotment of Shares 27/12/2007 Forms 88(2)R - Return of an Allotment of Shares 04/01/2008 Forms 88(2)R - Return of an Allotment of Shares 14/01/2008 Forms 88(2)R - Return of an Allotment of Shares 16/01/2008 Forms 88(2)R - Return of an Allotment of Shares 17/01/2008 Forms 88(2)R - Return of an Allotment of Shares 21/01/2008 Form 288a - Appointment of a Director 25/01/2008 Forms 88(2)R - Return of an Allotment of Shares 31/01/2008 Forms 88(2)R - Return of an Allotment of Shares 13/02/2008 Forms 88(2)R - Return of an Allotment of Shares 27/02/2008 Forms 88(2)R - Return of an Allotment of Shares 28/02/2008 Form 88(2)R - Return of an Allotment of Shares 06/03/2008 Form 88(2)R - Return of an Allotment of Shares 11/03/2008 Form 88(2)R - Return of an Allotment of Shares 12/03/2008 Form 88(2)R - Return of an Allotment of Shares 12/04/2008 Forms 88(2)R - Return of an Allotment of Shares 14/04/2008 Forms 88(2)R - Return of an Allotment of Shares 23/04/2008 Forms 88(2)R - Return of an Allotment of Shares 24/04/2008 Resolution - Cancellation of subscriber shares 24/04/2008 Articles of Association 24/04/2008 Form 122 12/05/2008 Resolutions - Scheme of arrangement; authority to allot shares and adoption of articles of association 15/05/2008 Forms 88(2)R - Return of an Allotment of Shares 19/05/2008 Form 122 19/05/2008 Resolution - Cancellation of special voting shares
3. Documents filed with the Securities and Exchange Commission ("SEC")
The Company submitted filings to the SEC in compliance with its obligations under national laws and rules dealing with the regulation of securities, issuers of securities and securities markets by virtue of having American Depository shares admitted to trading on the NASDAQ. Full details of these filings can be found on the SEC's website at www.sec.gov.
4. Documents sent to Shareholders
The following documents were published and sent to shareholders. They are available on the Company's website.
Date Document 17/09/2007 Interim Report 16/04/2008 Notice of Court Meeting 16/04/2008 Notice of Extraordinary General Meeting 16/04/2008 Circular - Recommend proposal to establish Shire Limited
A copy of this Annual Information Update and copies of the documents referred to in it can be obtained from the Deputy Company Secretary at the Company's registered office.
T MayCompany Secretary
For further information please contact:
Investor Relations Clĩa Rosenfeld (Rest of the World) +44 1256 894 160 Eric Rojas (North America) +1 484 595 8252 Notes to editorsSHIRE PLC
Shire's strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit and hyperactivity disorder (ADHD), human genetic therapies (HGT), gastrointestinal (GI) and renal diseases. The structure is sufficiently flexible to allow Shire to target new therapeutic areas to the extent opportunities arise through acquisitions. Shire's in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe. Shire believes that a carefully selected portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results.
For further information on Shire, please visit the Company's website: www.shire.com.
Hampshire International Business Park Chineham Basingstoke Hampshire RG24 8EP United Kingdom Tel +44 (0)1256 894000 Fax +44 (0)1256 894708 www.shire.com Press Release
Registered in England 5492592 Registered Office as above
vendorRelated Shares:
Shire